IntegraGen reports 6.4 M€ in revenues for the first half of 2022 representing 34% growth compared to H1 2021. Cash position of 4.5 M€.
13 Julho 2022 - 2:30AM
Business Wire
- Continued sustained growth associated with the company’s
sequencing platform in Évry and long-term contracts
- Strong revenue growth linked with microbiology sequencing
Regulatory News:
IntegraGen (FR0010908723 – ALINT ), an OncoDNA Group company
specializing in the decryption of the human genome which performs
interpretable genomic analyzes for academic and private
laboratories and develops diagnostic tools for oncology, today
announced its non-audited revenue of 6,439 k€ for the first half of
2022, representing an increase of 34% compared to H1 2021. This
sales growth across all of the company’s businesses reflects the
strong rebound of the general economic business climate compared to
H1 2021 which was significantly impacted by the global
pandemic.
R&D sequencing activities have resumed the pre-pandemic
growth trend and were fueled by several significant projects
realized on the company’s sequencing platform in Évry. The growth
was primarily a result of the strong demand for projects that were
initiated in Q2 2021. The sequencing platform also benefited from a
pandemic-related microbiology project during H1 which resulted from
site specific sequencing capacity limitations experienced by one of
the company’s partners, representing c. 7% of the company’s revenue
in H1. In parallel with the above, sequencing activities associated
with external platforms operated by IntegraGen continued to
experience increased output with new clinical research projects for
oncology also driving revenue growth.
The company’s cash position as of end of June 2022 was 4,489 k€,
a decrease of 0.3 M€ compared to December 31, 2021. This was in
line with the company’s expectations and 2022 budget. This decrease
was primarily due to change in working capital requirement. This
position includes a State guaranteed loan (Prêt Garanti par l’État,
PGE) totaling 1,763 k€, received at the beginning of 2020, that the
Company started to reimburse in June.
Despite a temporary slowdown in the booking orders as of end of
June, the company confirms its growth perspectives based on the
current sales dynamics and existing long-term contracts along with
the synergies now in place with the other entities of the OncoDNA
Group.
Bernard Courtieu, IntegraGen CEO, said “The revenue
generated during the first half of 2022 confirms the resilience of
IntegraGen’s business across each and every line of the company’s
business. The company is now well-positioned for the future with
rebound in the growth of our business seen in 2022 demonstrating
our growth potential. The company’s business remains driven by long
term contracts for the operation of external sequencing platforms
with additional benefits derived from solid commercial dynamics,
including the synergies we are now experiencing as a result of
being fully integrated into the OncoDNA Group.”
Full financial results for H1 2022 will be published on October
18, 2022.
ABOUT INTEGRAGEN
IntegraGen is an OncoDNA group company specializing in the
genomics of cancer and rare genetic diseases. Backed by highly
competent and qualified teams, IntegraGen is a leading player in
DNA sequencing services and genomic data interpretation software.
The company runs one of the largest NGS labs in France and operates
for research institutes of excellence. As part of OncoDNA group,
IntegraGen leverages the power of next generation sequencing with
the mission of delivering the promise of precision medicine to
patients. IntegraGen has about 50 employees and generated €10,8
million of turnover in 2021. Based in France, IntegraGen is part of
the Belgian OncoDNA group present in Spain, UK, Germany and works
with an international network of 35 distributors. The Group also
provides biomarker testing and clinical interpretation tools to
guide treatment and monitoring of latestage solid tumors and
accelerate the development of new cancer drugs.
IntegraGen is listed on Euronext Growth in Paris (ISIN:
FR0010908723 – Mnemo: ALINT – Eligible PEA- PME).
For further information, please visit www.integragen.com or
connect with us on LinkedIn or Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220712006022/en/
IntegraGen Bernard COURTIEU CEO
Pierre FLAMANT CFO
contact@integragen.com Tél. : +33 (0)1 60 91 09 00
NewCap Investore Relations Louis-Victor DELOUVRIER
integragen@newcap.eu Tél. : +33 (0)1 44 71 98 53
Integragen (EU:ALINT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Integragen (EU:ALINT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024